Minirin (Desmopressin)

Desmopressin, the active ingredient in Minirin, is a Vasopressin V2 receptor agonist presented as a sublingual tablet for sublingual use. It treats central diabetes insipidus, nocturnal enuresis, and certain bleeding disorders in appropriate patients.

GNH USA supplies Minirin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Desmopressin acts on the antidiuretic hormone pathway to regulate water balance and coagulation.

Central diabetes insipidus: reduces excessive urine output by increasing water reabsorption in the kidneys. Nocturnal enuresis: decreases nighttime bedwetting episodes by concentrating urine. Bleeding disorders (e.g., hemophilia A, von Willebrand disease): raises plasma levels of clotting factors to improve hemostasis.

Desmopressin may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Headache: mild to moderate intensity. - Nausea or abdominal discomfort. - Dry mouth or mild throat irritation. - Nasal congestion (if nasal formulation is used). - Mild hyponatraemia: low sodium without severe symptoms.

Serious or Rare Side Effects: - Severe hyponatraemia leading to seizures or coma. - Water intoxication with rapid weight gain. - Allergic reactions such as rash, itching or anaphylaxis. - Thrombotic events in patients with high clotting factor levels. - Hypertension due to fluid retention.

Desmopressin requires careful monitoring to avoid complications.

Monitor serum sodium: check electrolytes regularly, especially in at‑risk patients. Adjust dose in renal impairment: reduce dosage if kidney function is decreased. Limit fluid intake: advise patients to avoid excessive water consumption. Use caution in the elderly: increased sensitivity to water retention and hyponatraemia. Store at room temperature: keep below 25°C, protect from moisture and light.

Desmopressin can interact with several drug classes, affecting safety or efficacy.

Major Interactions (Avoid): - Carbamazepine: reduces desmopressin effectiveness. - Thiazide diuretics: increase risk of hyponatraemia. - NSAIDs: may potentiate water retention. - Other antidiuretic agents (e.g., vasopressin analogues): risk of severe hyponatraemia.

Moderate Interactions (Monitor Closely): - ACE inhibitors: monitor blood pressure and electrolytes. - SSRIs: watch for additive hyponatraemia. - Phenobarbital and other enzyme inducers: may lower plasma desmopressin levels.